Sirolimus is an mTOR inhibitor that blocks intracellular signaling pathways responsible for T-cell activation and proliferation.
It:
The drug arrests the cell cycle in the G1 phase.
Sirolimus has been extensively studied in transplantation medicine. Multicenter trials demonstrate reduced rates of acute rejection when used in combination immunosuppressive regimens.
Long-term studies show decreased chronic graft dysfunction and vascular smooth muscle proliferation. It is widely included in international immunosuppressive protocols.
The medication inhibits immune activation and protects transplanted organs.
Take orally once daily at the same time each day, strictly as prescribed by a healthcare provider. Swallow whole with water. Dosage is individualized based on clinical condition and blood concentration monitoring.
Contraindications
Side effects
